2012•TumoriRequires access
Magnesium isoglycyrrhizinate used in the treatment of chemotherapeutic drugs-induced acute liver dysfunction: A phase III clinical trial
Tang Li-na, Lin Feng, Zan Shen, Sun Yuan-jue, Yang Yao
Open publisher page 9 citations
Abstract
Objective: This study was designed to evaluate the efficacy and safety of magnesium isoglycyrrhizinate in the treatment of chemotherapeutic drugs-induced acute liver dysfunction. Methods: This was a multi-center, randomized, double-blind and positive-controlled phase Ⅲ clinical trial. Fifty-five eligible subjects were randomly divided in the ratio of 2:1 to receive magnesium isoglycyrrhizinate (n = 35; 200 mg/d for two weeks) or tiopronin (n = 20; 200 mg/d for two weeks). The change of liver function after treatment and the adverse effects were evaluated. Results: The overall response of the magnesium isoglycyrrhizinate-treated group after treatment for one week was 91.43%, which was much higher than that of the tiopronin-treated group (65.00%, P 0.05). Conclusion: Magnesium isoglycyrrhizinate exerts its desirable effect on chemotherapeutic drugs-induced acute liver dysfunction, with a shortening course of liver damage and fewer side effects. DOI:10.3781/j.issn.1000-7431.2012.09.012